Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 11,419 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions: Carboplatin, Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Laboratory Biomarker Analysis, Paclitaxel, Pegfilgrastim, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 631
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 408 more

Conditions: Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions: MDV3100; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 9
States / cities: Boston, Massachusetts • New York, New York • Portland, Oregon + 2 more

Conditions: Major Depression
Interventions: Pharmacogenetic Test; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 1,944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 24
States / cities: North Little Rock, Arkansas • Palo Alto, California • San Francisco, California + 21 more

Conditions: Multiple Sclerosis
Interventions: Discontinuation of disease modifying therapy, Standard of Care; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 19
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more

Conditions: Heart Failure, Cardiomyopathies
Interventions: EXCOR Pediatric; Device
Lead sponsor: Berlin Heart, Inc; Industry
Eligibility: 1 Day to 16 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 12 more

Conditions: Left Sided Heart Failure
Interventions: HeartWare HVAD, Thoracotomy; Device · Procedure
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 19 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 25
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 21 more

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Pemetrexed, Gemcitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 6
States / cities: Aurora, Colorado • Plantation, Florida • Morrisville, North Carolina + 3 more

Conditions: Shock, Traumatic
Interventions: 7.5% hypertonic saline/6% Dextran-70 (HSD), 7.5% hypertonic saline (HS), 0.9% normal saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more

Conditions: COVID-19
Interventions: BRII-196, BRII-198, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 76
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Dapagliflozin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 150 Years
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 25
States / cities: Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more

Conditions: Bronchiolitis Obliterans
Interventions: fluticasone propionate, montelukast sodium, azithromycin; Drug
Lead sponsor: Stephanie Lee; Other
Eligibility: 6 Years to 99 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Scottsdale, Arizona • Stanford, California • Tampa, Florida + 8 more

Conditions: Asthma
Interventions: Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Insulin Resistance, Type 2 Diabetes Mellitus
Interventions: pioglitazone, nateglinide, placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 55 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 2
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Essential Tremor
Interventions: Transcranial ExAblate; Device
Lead sponsor: InSightec; Industry
Eligibility: 22 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 7
States / cities: Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 4 more

Conditions: Colorectal Cancer Metastatic
Interventions: nab-sirolimus; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Scottsdale, Arizona • New Orleans, Louisiana • Las Vegas, Nevada + 3 more

Conditions: HIV Infections
Interventions: Anti-HIV Immune Serum Globulin (Human); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 12 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 37
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more

Conditions: Prostate Cancer
Interventions: bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 91
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: Urinary Bladder, Overactive
Interventions: solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 104
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more

Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation; Drug · Other · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 3
States / cities: Salt Lake City, Utah • Seattle, Washington

Conditions: Papilloma Viral Infection
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 9 Years to 17 Years · Female only
Enrollment: 1,321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Tucker, Georgia • Baltimore, Maryland • Kansas City, Missouri + 4 more

Conditions: Endometrial Cancer
Interventions: Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 57
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 50 more

Conditions: HIV Infections, Pregnancy
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 60 Years
Enrollment: 1,496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 58
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more

Conditions: Dyslipidemia
Interventions: Placebo, Pravastatin, Dalcetrapib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 33
States / cities: Mobile, Alabama • Scottsdale, Arizona • Newark, Delaware + 30 more

Conditions: Tuberculosis
Interventions: BCG Vaccine USP, Isoniazid, Rifampin; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

PRIME Care (PRecision Medicine In MEntal Health Care)

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device

HW006 LATERAL Thoracotomy

Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy

Hypertonic Resuscitation Following Traumatic Injury

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Targeted Therapy of Bronchiolitis Obliterans Syndrome

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

Continued Access Protocol: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors

Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Immunogenicity of Off-Schedule Dosing of HPV Vaccine

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines